FFA
BIO icon

Farther Finance Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Farther Finance Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$290K Buy
768
+7
+0.9% +$2.44K ﹤0.01% 2010
2026
Q2 		$223K Buy
761
+622
+447% +$176K ﹤0.01% 2165
2026
Q1 		$38.7K Sell
139
-45
-24% -$13K ﹤0.01% 3187
2025
Q4 		$55.8K Buy
184
+80
+77% +$25K ﹤0.01% 2746
2025
Q3 		$29.2K Buy
104
+36
+53% +$9.8K ﹤0.01% 2787
2025
Q2 		$16.4K Buy
68
+10
+17% +$2.36K ﹤0.01% 2802
2025
Q1 		$13.9K Sell
58
-58
-50% -$17.4K ﹤0.01% 2577
2024
Q4 		$38.1K Sell
116
-11
-9% -$3.73K ﹤0.01% 1791
2024
Q3 		$42.5K Buy
127
+26
+26% +$8.26K ﹤0.01% 1741
2024
Q2 		$26.7K Sell
101
-51
-34% -$14.8K ﹤0.01% 1669
2024
Q1 		$51.5K Buy
152
+41
+37% +$13.5K ﹤0.01% 1181
2023
Q4 		$35.8K Buy
111
+32
+41% +$10K ﹤0.01% 1147
2023
Q3 		$28.3K Sell
79
-22
-22% -$8.49K ﹤0.01% 985
2023
Q2 		$38.3K Buy
101
+30
+42% +$12.2K 0.01% 751
2023
Q1 		$34K Buy
71
+13
+22% +$6.09K 0.01% 726
2022
Q4 		$24.4K Buy
+58
New +$23.4K 0.01% 671

Other funds holding BIO

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return

Farther Finance Advisors's BIO Position: Q3 2026 in Review

Farther Finance Advisors increased its Bio-Rad Laboratories Class A (BIO) stake by 0.92% in Q3 2026, buying an estimated $2.44K and bringing the position to 768 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #2010.

Farther Finance Advisors first reported a position in BIO in Q4 2022 and has held it in 16 quarters since. 10 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • Farther Finance Advisors held 768 shares of Bio-Rad Laboratories Class A worth $290K as of Q3 2026.
  • Farther Finance Advisors bought 7 Bio-Rad Laboratories Class A shares in Q3 2026, an estimated $2.44K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #2010 holding.
  • Farther Finance Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and has held it in 16 quarters since.
  • 10 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.